Trial Profile

A Phase Ib/II Clinical Trial of Nous-209 for Recurrent Neoantigen Immunogenicity and Cancer Immune Interception in Lynch Syndrome

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 29 Oct 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NOUS-209 (Primary)
Indications Hereditary nonpolyposis colorectal cancer
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

19 Oct 2026 According to a Nouscom media release, company announced the closing of an oversubscribed EURO 120 million (USD 135 million) Series D financing to support this clinical trial.
20 Jul 2026 According to a Nouscom media release, data from the trial will be presented at the European Society for Medical Oncology (ESMO) Congress 2026
01 Jun 2026 According to a Nouscom media release, data published from the successfully completed phase 1b trial were published in Science Translational Medicine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com